CRISPR-Cas-based detection of Mycobacterium tuberculosis: current advances and translational bottlenecks.
It is highlighted that successful clinical translation of CRISPR-based TB diagnostics is determined more by real-world adaptability than by analytical performance alone, and the variability in assay design, analytical and clinical performance, and translational readiness across currently available systems is evaluated.